Form 4: Seres Therapeutics Officer Reports Routine Stock Transactions

Seres Therapeutics' EVP, Chief Commercial & Strategy Officer, Teresa L. Young, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, Inc. (MCRB), reported changes in her beneficial ownership of common stock.
• On August 15, 2025, Young acquired a total of 230 shares of common stock (133 shares and 97 shares) through the vesting of restricted stock units (RSUs).
• Following these acquisitions, her direct beneficial ownership of common stock increased to 5,274 shares.
• On August 18, 2025, Young sold 59 shares of common stock at a price of $16.65 per share.
• This sale was executed under a Rule 10b5-1 plan adopted on March 5, 2023, specifically to cover tax obligations related to the RSU vesting.
• After the sale, Young's direct beneficial ownership of common stock stands at 5,215 shares.

Sentiment

Score: 5

Explanation: The filing details routine insider transactions (RSU vesting and tax-related sale) under a pre-established plan, which is neutral in terms of company sentiment.

Positives

• Vesting of restricted stock units indicates continued compensation for the executive, aligning her interests with shareholders.
• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, demonstrating adherence to insider trading regulations and transparency.

Negatives

• The sale of 59 shares, while for tax purposes, represents a minor reduction in the executive's direct equity holding.

Future Outlook

The remaining restricted stock units from the first grant (vested 25% on Feb 15, 2024) and the second grant (vested 25% on Feb 15, 2025) are scheduled to vest and settle in 12 equal quarterly installments thereafter, with no expiration date.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

Industry Context

This filing represents a routine insider transaction related to executive compensation, common across publicly traded companies where executives receive equity as part of their remuneration. Such transactions, especially when pre-planned under Rule 10b5-1 for tax purposes, typically do not reflect a change in the executive's outlook on the company's prospects or broader industry trends.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for pre-scheduled stock sales to cover tax liabilities associated with RSU vesting is a standard practice among executives in publicly traded companies, aligning with corporate governance best practices to mitigate concerns about insider trading.
• The vesting schedule of restricted stock units, with initial vesting and subsequent quarterly installments, is a common structure for long-term incentive plans designed to retain executives and align their interests with shareholders over time, comparable to practices at biotech peers like Moderna or BioNTech.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact as these are routine, pre-planned executive compensation transactions and not indicative of a change in company fundamentals or executive confidence.
• Employees: No direct impact on general employees, but reflects standard executive compensation practices.

Next Steps

• Remaining restricted stock units will continue to vest and settle in 12 equal quarterly installments.

Key Dates

Keywords

Seres Therapeutics, MCRB, Form 4, insider transaction, stock vesting, executive compensation, Rule 10b5-1, common stock, equity